Angiotensin II receptor blockers and oral squamous cell carcinoma survival: A propensity-score-matched cohort study.
Ching-Nung WuShao-Chun WuWei-Chih ChenYao-Hsu YangJo-Chi ChinChih-Yen ChienFu-Min FangShau-Hsuan LiSheng-Dean LuoTai-Jan ChiuPublished in: PloS one (2021)
ARB use for more than 180 days is associated with an increased survival rate and is a positive, independent prognostic factor in patients with OSCC. A further two-arm study should be conducted to confirm the clinical usefulness of ARBs in OSCC patients.